Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04528953
Other study ID # STUDY00146006
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 13, 2020
Est. completion date October 2022

Study information

Verified date May 2022
Source University of Kansas Medical Center
Contact Batool Alkhamis, MS
Phone 8167431152
Email balkhamis@kumc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Knee osteoarthritis (KOA) causes pain and limited function that leads to a sedentary lifestyle. The sedentary lifestyle increases the risk of cardiovascular diseases. In addition, many subjects with KOA have knee pain and sleep disturbance that limit their function, quality of life and cause body fatigue. Walking exercise can benefit people with KOA. However, continues walking for more than 30 minutes can increase pain that may stop people from participation in walking exercise. Interval walking may complete the same amount of walking exercise in several separate time periods, without causing extra pain in people with KOA. Mind-body exercise may improve sleep and pain in people with KOA. This study will help researchers to find out whether the interval walking, or mind-body exercise may help people with KOA to improve their pain, fitness level, sleep quality, exercise participation, fatigue, and quality of life. By doing this study, researchers hope to learn more about the interval walking or mind-body exercise in people with KOA.


Recruitment information / eligibility

Status Recruiting
Enrollment 45
Est. completion date October 2022
Est. primary completion date August 2022
Accepts healthy volunteers No
Gender All
Age group 45 Years to 79 Years
Eligibility Inclusion criteria are the following: 1. 60-79 years of age and diagnosed with KOA by a physician or meet the ACR criteria (95% sensitivity, and 69% specificity) for KOA. The ACR criteria include experiencing almost daily knee pain and having at least 3 of these 6 criteria: (1) Age more than 50 years old, (2) less than 30 minutes of morning stiffness, (3) increased warmth of the knee, (4) crepitus with flexion or extension, (5) joints' bony enlargement , and (6) tenderness of joint line with palpation, or subject must be diagnosed radiologically, with grade II or more according to the Kellgren and Lawrence rating scale. 2. Frequent knee pain or aching on most of the preceding 30 days. 3. An average of mild to moderate pain intensity level (5 to 75 mm on the 100 mm VAS) in the last 7 days 4. Sedentary lifestyle assessed using 2011 Compendium of Physical Activities questionnaire. The subject is considered sedentary if engaging in exercise or physical activity with metabolic equivalents of task (MET) less than 4, not more than two times/week. Exclusion criteria: 1. Unwilling to attend 3 sessions/week at Kirmayer Fitness Center 2. Having other types of arthritis such as rheumatoid arthritis or gout 3. Neurological disorders 4. CVD including hypertension that prevent them from engaging in walking exercise 5. Currently using beta blocker medication 6. Underwent any lower limb surgery during the past 6 months 7. A history of two or more incidents of fall during the last 6 months 8. Current hip or spine pain that prevents them from engaging in walking exercise.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Interval walking and Qigong exercise
Interval walking: The subjects will be asked to complete daily 30 minutes of walking in two 15-minute bouts with the rest interval for at least 0.5 an hour and not more than 2 hours between each bout. Qigong exercise: mind-body exercise using the "six healing sound" Qigong exercise will be used because it is easy to learn, requires minimal physical capability, and can be performed even in a sitting body position.

Locations

Country Name City State
United States Wen Liu Kansas City Kansas

Sponsors (1)

Lead Sponsor Collaborator
University of Kansas Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility measurement: recruitment, compliance, and dropout Feasibility will be quantified using rates of participant recruitment, compliance, and dropout rate from the exercise program using exercise diary filled by the exercise supervisor. The Percentage of recruited subjects per month will be reported. The dropout rate is defined as the percentage of subjects who do not complete the study intervention and choose to withdraw. The compliance is defined as the percentage of the completed exercise program. The exercise diary log of subjects who drop out of the study will not be included when compliance is calculated. (feasibility measures will be reported in percentage) 6 week
Primary Acceptability Acceptability will be assessed via participants' program evaluation scores and rating of treatment satisfaction at the end-intervention evaluation. The subjects will be asked to score, on an 11-point scale, ranging from 0 (poor) to 10 (excellent) for questions "How do you rate this exercise program overall in regarding to ease of use?" and "How do you rate this exercise program overall in regarding to improving your symptoms?" Participants will be also asked to rate their overall level of satisfaction with the intervention using an 11-point numerical rating scale ranging from 0 (completely dissatisfied) to 10 (completely satisfied). 6 week
Secondary Comprehensive pain assessment: the Measure of Intermittent and Constant Osteoarthritis Pain For comprehensive pain assessment: The Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP) scale. ICOAP is a multidimensional measure developed to evaluate the pain in subjects with KOA, comprehensively. ICOAP assesses both pain intensity and frequency in addition to assessing the impact of pain on sleep, and quality of life (physical function). ICOAP has high reliability (0.85) and validity (0.60-0.81). ICOAP is 11-points scale to assess OA pain with maximum score 100. 6 week
Secondary Resting heart rate (rHR) and heart rate recovery (HRR) rHR and HRR will be measured using a Polar OH1 optical HR sensor (Polar Electro Inc., New York), which is in high agreement with ECG measured HR and is validated to be used in lab sittings. HRR is defined as the range of the change of HR from the peak after the exercise to one-minute post-exercise. Slow HRR is a warning of decline of cardiovascular/autonomic function. The HR should decrease at least 12 beats after one minute after exercise termination, otherwise this is considered as an abnormal response. The HRR will be measured post the 6-minute walk test, which has been approved to be as effective in testing HRR as vigorous exercises. The HR will be measured before the exercise (rHR), immediately after the exercise (the peak HR), and one minute after the exercise(1-min-post). Then, the difference between the peak HR and the 1-min-post will be calculated. 6 week
Secondary Heart rate variability (HRV) HRV will be estimated using an ECG system via analyzing the HRV frequency and time domain. Standard lead II configuration will be used by placing three disposable electrodes over the participant's chest to record the ECG signals. We will collect the ECG signal at 2000 Hz sampling rate.The subject will be asked to sit relaxed in a quiet room with a temperature between 22 and 24°C, for 10 minutes. Then, the HRV ECG recording will be collected over a 5-minute period while participants are asked to not move or speak over the next 5 minutes when HRV will be collected. BIOPAC AcqKnowledge 5.0 software will be utilized to collect both the frequency and the time parameters of HRV. The frequency parameters are LF power (0.04-0.15 Hz) and HF power (0.15-0.4 Hz) and LF/HF ratio, while the time parameters includes RMSSD. 6 week
Secondary Blood pressure SBP will be measures using an automatic device, Microlife BP monitor. 6 week
Secondary insomnia severity Insomnia Severity Index is a 7-item questionnaire that is a global measure of perceived insomnia severity, with its reliability and validity have been reported. 6 week
Secondary Sleeping Quality: Pittsburgh Sleep Quality Index Sleeping Quality Assessment will use Pittsburgh Sleep Quality Index (PSQI) with high test-retest reliability and construct validity. 6 week
Secondary Fatigue: Multidimensional Fatigue Inventory (MFI-20) Fatigue will be measured using Multidimensional Fatigue Inventory (MFI-20), with proved internal consistency, validity, and utilized in research of OA. 6 week
Secondary Depression: Geriatric Depression Scale The 15-item questionnaire of the Geriatric Depression Scale will be used, which is a valid measurement of depression. 6 week
Secondary Knee Injury and Osteoarthritis Outcome Score Injury and Osteoarthritis Outcome Score (KOOS) is a valid and reliable instrument and will be used for short-term and long-term follow-up of knee OA. KOOS consists of 42 items. A Likert scale is used for each sub-scale and items have five possible answer options scored from 0 (No Problems) to 4 (Extreme Problems) and each of the five scores is calculated as the sum of the items included. Scores are transformed to a 0-100 scale. Zero representing extreme knee problems and 100 representing no knee problems.
in 5 separately scored subscales; Pain, other Symptoms, Function in daily living (ADL), Function in Sport and Recreation (Sport/Rec), and knee-related Quality of Life (QOL).
6 week
Secondary 36 short form Quality of Life The SF-36 measures eight scales: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. 6 week
Secondary Inflammatory biomarkers The inflammatory biomarker assessments will use venous blood samples drawn from subjects. Approximately 10 ml of blood will be collected from fasting subjects, between 8 am to 10 am. The serum will be assayed for the levels of inflammatory markers: TNF-a, IL-1ß, IL-6, IL-8, IL-17, and C-reactive protein, using respective ELISA kits available from Thermo Scientific, Inc (Rockford, IL). 6 week
Secondary Fitness level- The 6-minute walk test The 6-minute walk test will be used to assess the fitness level at the baseline and after completing the intervention. We will follow the guideline of the American Thoracic Society to conduct this test as the improvement in walking distance indicates the improvement of aerobic fitness. 6 week
Secondary Pain intensity measurement Pain intensity level will be assessed using 100 mm horizontal VAS, which is a valid and reliable pain scale. The VAS is reported to be a sensitive measurement to hourly and weekly assessment of pain level, and a reduction of 10mm is reported to be the minimum clinical important difference for people with chronic pain such as in OA. The subjects in both groups will be asked to score their pain before and after each session of the walking exercise, and the averaged range of change from pre to post walking will be used in data analysis.
In addition, for change of pain from baseline to post intervention, the participant will be asked to report their minimum and maximum pain during the last 24 hours, and their current pain on the VAS ruler. Then, the average of the measure taken 3 different times will be used in the analysis.
6-week
See also
  Status Clinical Trial Phase
Recruiting NCT03895489 - Effectiveness of the Journey Total Knee Arthroplasty Versus Two Standard of Care Total Knee Arthroplasty Prostheses N/A
Completed NCT03660943 - A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain Phase 3
Completed NCT04531969 - Comparison of Outpatient and Inpatient Spa Therapy N/A
Completed NCT02848027 - Correlating the Osteoarthritic Knee Microenvironment to Clinical Outcome After Treatment With Regenexx®SD Treatment Phase 3
Completed NCT05160246 - The Instant Effect of Kinesiology Taping in Patients With Knee OA N/A
Recruiting NCT06080763 - Biomechanics and Clinical Outcomes in Responders and Non-Responders
Completed NCT03643588 - The Comparison of HYAJOINT Plus and Hyalgan Hyaluronan Supplement for Knee Osteoarthritis Pain N/A
Active, not recruiting NCT05100225 - Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis Phase 2
Active, not recruiting NCT04061733 - New Hydroxyethyl Cellulose Hydrogel for the Treatment of the Pain of Knee Arthrosis N/A
Completed NCT04051489 - A Novel Smartphone Application for "Smart" Knee Osteoarthritis Trials
Recruiting NCT05546541 - Epidemiology and Nutrition
Recruiting NCT05447767 - Prediction AlgoriThm for regeneraTive Medicine Approach in knEe OA: New Decision-making Process Based on Patient pRofiliNg Phase 2
Not yet recruiting NCT04448106 - Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis Phase 2
Not yet recruiting NCT03225911 - Effect of a Lateral Wedge Insole and Simple Knee Sleeve in Individuals With Knee Osteoarthritis N/A
Completed NCT05070871 - A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women N/A
Completed NCT05703087 - Positive Cueing in Knee Arthroplasty. N/A
Not yet recruiting NCT06042426 - Effects of Perioperative Intravenous Dexamethasone in Clinical Outcomes After Total Knee Arthroplasty in a Hispanic Population Phase 4
Completed NCT02901964 - Effect of Strengthening the Hip Abductor in Patients With Knee Osteoarthritis: Randomized Controlled Trial N/A
Completed NCT03037489 - A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients Phase 2
Completed NCT02905747 - The Effect of Medical Exercise Therapy on Pain, Function and Physical Activity in Patients With Knee Osteoarthritis N/A